(A) Overall survival for BCL2-rearrangement positive (n = 25) and BCL2-rearrangement negative (n = 131) lymphomas. (B) DFS for BCL2-rearrangement positive (n = 11) and BCL2-rearrangement negative (n = 77) lymphomas.